245 related articles for article (PubMed ID: 31549264)
1. Developing real-world comparators for clinical trials in chemotherapy-refractory patients with gastric cancer or gastroesophageal junction cancer.
Chau I; Le DT; Ott PA; Korytowsky B; Le H; Le TK; Zhang Y; Sanchez T; Maglinte GA; Laurie M; Abraham P; Patel D; Shangguan T
Gastric Cancer; 2020 Jan; 23(1):133-141. PubMed ID: 31549264
[TBL] [Abstract][Full Text] [Related]
2. Real-world Treatment Patterns and Clinical Outcomes Across Lines of Therapy in Patients With Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer.
Le DT; Ott PA; Korytowsky B; Le H; Le TK; Zhang Y; Maglinte GA; Abraham P; Patel D; Shangguan T; Chau I
Clin Colorectal Cancer; 2020 Mar; 19(1):32-38.e3. PubMed ID: 31813769
[TBL] [Abstract][Full Text] [Related]
3. Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer.
Satoh T; Kang YK; Chao Y; Ryu MH; Kato K; Cheol Chung H; Chen JS; Muro K; Ki Kang W; Yeh KH; Yoshikawa T; Oh SC; Bai LY; Tamura T; Lee KW; Hamamoto Y; Kim JG; Chin K; Oh DY; Minashi K; Cho JY; Tsuda M; Tanimoto M; Chen LT; Boku N
Gastric Cancer; 2020 Jan; 23(1):143-153. PubMed ID: 31087200
[TBL] [Abstract][Full Text] [Related]
4. A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data.
Chen LT; Satoh T; Ryu MH; Chao Y; Kato K; Chung HC; Chen JS; Muro K; Kang WK; Yeh KH; Yoshikawa T; Oh SC; Bai LY; Tamura T; Lee KW; Hamamoto Y; Kim JG; Chin K; Oh DY; Minashi K; Cho JY; Tsuda M; Sameshima H; Kang YK; Boku N
Gastric Cancer; 2020 May; 23(3):510-519. PubMed ID: 31863227
[TBL] [Abstract][Full Text] [Related]
5. A Comparison of Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving First-Line Therapy for Unresectable Advanced Gastric or Gastroesophageal Junction Cancer Versus Esophageal Adenocarcinomas.
Shankaran V; Xiao H; Bertwistle D; Zhang Y; You M; Abraham P; Chau I
Adv Ther; 2021 Jan; 38(1):707-720. PubMed ID: 33244736
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of nivolumab versus clinical practice for advanced gastric or gastroesophageal junction cancer.
Chau I; Ayers D; Goring S; Cope S; Korytowsky B; Abraham P
J Comp Eff Res; 2020 Jan; 9(2):103-114. PubMed ID: 31872771
[No Abstract] [Full Text] [Related]
7. Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial.
Chung HC; Arkenau HT; Lee J; Rha SY; Oh DY; Wyrwicz L; Kang YK; Lee KW; Infante JR; Lee SS; Kemeny M; Keilholz U; Melichar B; Mita A; Plummer R; Smith D; Gelb AB; Xiong H; Hong J; Chand V; Safran H
J Immunother Cancer; 2019 Feb; 7(1):30. PubMed ID: 30717797
[TBL] [Abstract][Full Text] [Related]
8. Nivolumab in gastric/gastroesophageal junction cancer: real-world data from UK Early Access to Medicines Scheme.
Soni M; Kiff C; Carroll R; Stein D; Saragoussi D; Nassar A; Maisey N; Tyas D
Future Oncol; 2021 Aug; 17(24):3163-3174. PubMed ID: 34098737
[TBL] [Abstract][Full Text] [Related]
9. A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2).
Kato K; Satoh T; Muro K; Yoshikawa T; Tamura T; Hamamoto Y; Chin K; Minashi K; Tsuda M; Yamaguchi K; Machida N; Esaki T; Goto M; Komatsu Y; Nakajima TE; Sugimoto N; Yoshida K; Oki E; Nishina T; Tsuji A; Fujii H; Kunieda K; Saitoh S; Omuro Y; Azuma M; Iwamoto Y; Taku K; Fushida S; Chen LT; Kang YK; Boku N
Gastric Cancer; 2019 Mar; 22(2):344-354. PubMed ID: 30506519
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics analysis of nivolumab in Asian and non-Asian patients with gastric and gastro-esophageal junction cancers.
Osawa M; Hasegawa M; Bello A; Roy A; Hruska MW
Cancer Chemother Pharmacol; 2019 Apr; 83(4):705-715. PubMed ID: 30666395
[TBL] [Abstract][Full Text] [Related]
11. First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis.
Liu T; Bai Y; Lin X; Li W; Wang J; Zhang X; Pan H; Bai C; Bai L; Cheng Y; Zhang J; Zhong H; Ba Y; Hu W; Xu R; Guo W; Qin S; Yang N; Lu J; Shitara K; Lei M; Li M; Bao N; Chen T; Shen L
Int J Cancer; 2023 Feb; 152(4):749-760. PubMed ID: 36121651
[TBL] [Abstract][Full Text] [Related]
12. CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer.
Janjigian YY; Bendell J; Calvo E; Kim JW; Ascierto PA; Sharma P; Ott PA; Peltola K; Jaeger D; Evans J; de Braud F; Chau I; Harbison CT; Dorange C; Tschaika M; Le DT
J Clin Oncol; 2018 Oct; 36(28):2836-2844. PubMed ID: 30110194
[TBL] [Abstract][Full Text] [Related]
13. Checkpoint inhibitors in metastatic gastric and GEJ cancer: a multi-institutional retrospective analysis of real-world data in a Western cohort.
Schlintl V; Huemer F; Rinnerthaler G; Melchardt T; Winder T; Reimann P; Riedl J; Amann A; Eisterer W; Romeder F; Piringer G; Ilhan-Mutlu A; Wöll E; Greil R; Weiss L
BMC Cancer; 2022 Jan; 22(1):51. PubMed ID: 35012477
[TBL] [Abstract][Full Text] [Related]
14. Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial.
Liu T; Qin Y; Li J; Xu R; Xu J; Yang S; Qin S; Bai Y; Wu C; Mao Y; Wu H; Ge Y; Shen L
Cancer Commun (Lond); 2019 Jun; 39(1):38. PubMed ID: 31234927
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kang YK; Boku N; Satoh T; Ryu MH; Chao Y; Kato K; Chung HC; Chen JS; Muro K; Kang WK; Yeh KH; Yoshikawa T; Oh SC; Bai LY; Tamura T; Lee KW; Hamamoto Y; Kim JG; Chin K; Oh DY; Minashi K; Cho JY; Tsuda M; Chen LT
Lancet; 2017 Dec; 390(10111):2461-2471. PubMed ID: 28993052
[TBL] [Abstract][Full Text] [Related]
16. Palliative chemotherapy for gastroesophageal cancer in old and very old patients: A retrospective cohort study at the National Center for Tumor Diseases, Heidelberg.
Berger AK; Zschaebitz S; Komander C; Jäger D; Haag GM
World J Gastroenterol; 2015 Apr; 21(16):4911-8. PubMed ID: 25945004
[TBL] [Abstract][Full Text] [Related]
17. Correlation of trastuzumab-based treatment with clinical characteristics and prognosis in HER2-positive gastric and gastroesophageal junction cancer: A retrospective single center analysis.
Ilhan-Mutlu A; Taghizadeh H; Beer A; Dolak W; Ba-Ssalamah A; Schoppmann SF; Hejna M; Birner P; Preusser M
Cancer Biol Ther; 2018 Mar; 19(3):169-174. PubMed ID: 29252101
[TBL] [Abstract][Full Text] [Related]
18. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.
Catenacci DVT; Tebbutt NC; Davidenko I; Murad AM; Al-Batran SE; Ilson DH; Tjulandin S; Gotovkin E; Karaszewska B; Bondarenko I; Tejani MA; Udrea AA; Tehfe M; De Vita F; Turkington C; Tang R; Ang A; Zhang Y; Hoang T; Sidhu R; Cunningham D
Lancet Oncol; 2017 Nov; 18(11):1467-1482. PubMed ID: 28958504
[TBL] [Abstract][Full Text] [Related]
19. Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study.
Kang YK; Morita S; Satoh T; Ryu MH; Chao Y; Kato K; Chung HC; Chen JS; Muro K; Kang WK; Yeh KH; Yoshikawa T; Oh SC; Bai LY; Tamura T; Lee KW; Hamamoto Y; Kim JG; Chin K; Oh DY; Minashi K; Cho JY; Tsuda M; Sameshima H; Chen LT; Boku N
Gastric Cancer; 2022 Jan; 25(1):207-217. PubMed ID: 34480657
[TBL] [Abstract][Full Text] [Related]
20. Ramucirumab for the treatment of patients with gastric or gastroesophageal junction cancer in community oncology practices.
Paulson AS; Hess LM; Liepa AM; Cui ZL; Aguilar KM; Clark J; Schelman W
Gastric Cancer; 2018 Sep; 21(5):831-844. PubMed ID: 29397460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
